J Gynecol Oncol.
2022 Jul;33(4):e64. 10.3802/jgo.2022.33.e64.
A step towards the ambition of precision oncology in recurrent ovarian cancer
- Affiliations
-
- 1Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore
- 2Cancer Science Institute, National University of Singapore, Singapore
- 3Yong Loo Lin School of Medicine, National University of Singapore, Singapore
- KMID: 2537901
- DOI: http://doi.org/10.3802/jgo.2022.33.e64
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
- The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
- Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
- Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer
- Maximal cytoreductive effort in epithelial ovarian cancer surgery
